Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics centers on allegations that the company misrepresented the clinical efficacy of its Nanobody structure compared to traditional monoclonal antibodies, particularly in the context of the Phase 3 VELA trials [2][3]. Legal Allegations - The lawsuit claims that MoonLake failed to disclose that its product SLK shares the same molecular targets as BIMZELX, a competitor, which undermines its claimed competitive advantage [3]. - Allegations include that the company misrepresented the Nanobody's ability to provide superior clinical efficacy, specifically in treating hidradenitis suppurativa [3]. - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these issues [3]. Financial Impact - Investors who purchased MLTX shares during the Class Period (March 10, 2024, through September 29, 2025) and experienced significant losses are encouraged to participate in the lawsuit [4]. - Hagens Berman has a history of securing over $2.9 billion in settlements for investors in similar cases, indicating a strong potential for recovery [4][7]. Next Steps for Investors - The deadline for investors to move for appointment as lead plaintiff in the class action lawsuit is December 15, 2025 [1][5]. - Investors are urged to contact Hagens Berman for more information and to discuss their losses related to MoonLake [5][6].

Core Viewpoint - Holzer & Holzer, LLC is reminding investors of deadlines to seek lead plaintiff status in several class action lawsuits against companies including MoonLake Immunotherapeutics, DexCom, and Synopsys, alleging misleading statements and failure to disclose material facts during specified periods [1][2][3]. Group 1: MoonLake Immunotherapeutics (MLTX) - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company made materially false and/or misleading statements regarding SLK's superiority to monoclonal antibodies between March 10, 2024, and September 29, 2025 [1]. - Investors who purchased shares during this period and suffered significant losses are encouraged to discuss their legal rights [1]. Group 2: DexCom, Inc. (DXCM) - A class action lawsuit has been filed against DexCom, alleging that the company made materially false and/or misleading statements regarding design changes to its G6 and G7 products between January 8, 2024, and September 17, 2025 [2]. - Investors who purchased shares during this period and suffered significant losses are encouraged to discuss their legal rights [2]. Group 3: Synopsys, Inc. (SNPS) - A class action lawsuit has been filed against Synopsys, alleging that the company made materially false and/or misleading statements regarding the economics of its Design IP business between December 4, 2024, and September 9, 2025 [3]. - Investors who purchased shares during this period and suffered significant losses are encouraged to discuss their legal rights [3]. Group 4: Holzer & Holzer, LLC - Holzer & Holzer, LLC is recognized as a top-rated securities litigation law firm and has been involved in recovering hundreds of millions of dollars for shareholders affected by fraud and corporate misconduct since its founding in 2000 [4]. - The firm is dedicated to representing shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years, highlighting its expertise in complex securities cases [4].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with investors having until December 15, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically targeting moderate to severe hidradenitis suppurativa with its investigational drug sonelokimab [3][4]. - The company previously claimed that its clinical data indicated a superior clinical benefit and differentiation of sonelokimab compared to competitors [4]. Group 3: Clinical Trial Results - The Phase 3 VELA trials for sonelokimab reported disappointing results, with VELA-2 failing to meet its primary endpoint, raising concerns about the drug's regulatory approval and commercial viability [5][6]. - Following the announcement of the trial results on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - The Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that the defendants made false and misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, which led to investor damages when the truth was revealed [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in recent years [5].

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moonlake-loss-submission-form/?id=179740&from=3 CLASS PERIOD: March 10 ...

Core Insights - The lawsuit against MoonLake Immunotherapeutics, Inc. alleges that the company concealed material adverse facts regarding the clinical performance of its drug SLK, particularly in comparison to competitors like BIMZELX [2][3] - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these alleged misrepresentations [3] Legal Allegations - The lawsuit focuses on the alleged failure of MoonLake to disclose that SLK shares the same molecular targets as BIMZELX, which could mislead investors about its competitive positioning [3] - It is claimed that MoonLake misrepresented the efficacy of its Nanobody structure, suggesting it would provide superior clinical outcomes for treating hidradenitis suppurativa [3] - The legal focus includes whether investors are entitled to damages due to the alleged wrongful acts and omissions during the class period [3] Investor Actions - Investors who purchased MLTX shares between March 10, 2024, and September 29, 2025, and suffered losses are encouraged to contact Hagens Berman for potential legal action [4] - The deadline for investors to move the court for appointment as lead plaintiff is December 15, 2025 [1][5] Firm Background - Hagens Berman has a strong track record, having secured over $2.9 billion in settlements for investors in similar cases [4][6] - The firm specializes in corporate accountability and represents various stakeholders, including investors and whistleblowers [6]

PHILADELPHIA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the “Class Period”). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plainti ...

MLTX CLASS NOTICE: MoonLake Immunotherapeutics Securities Class Action Lawsuit is Pending, Investors Notified to Contact BFA Law by December 15December 08, 2025 8:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 8, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal se ...

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 15, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 2: Case Allegations - The complaint alleges that during the class period, the defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, specifically concerning its molecular targets and clinical benefits [5]. - The lawsuit claims that when the true information was revealed, investors suffered damages due to the misleading nature of the defendants' statements [5].